Stockscreener 앱 받기
0.7556
2.67%
-0.0207
Palisade Bio Inc 주식(PALI)의 최신 뉴스
FY2025 EPS Estimates for Palisade Bio Increased by Analyst - American Banking and Market News
FY2025 EPS Forecast for Palisade Bio Raised by Analyst - Defense World
Analysts Issue Forecasts for Palisade Bio Q1 Earnings - Defense World
Palisade Bio reports safe PALI-2108 trials, eyes H1 2025 data - Investing.com Canada
Palisade Bio reports safe PALI-2108 trials, eyes H1 2025 data By Investing.com - Investing.com South Africa
Palisade Bio Completes Dosing In Phase 1A Portion Of Ongoing Phase 1A/B Study Of Pali-2108 - MarketScreener
Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Clinical Trial Success: Palisade Bio's UC Treatment Achieves Key Safety Milestone - Stock Titan
PALI stock plunges to 52-week low, touches $0.64 amid market challenges - Investing.com Australia
Palisade Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Palisade Bio Inc. (PALI) reports earnings - qz.com
PALI stock plunges to 52-week low, hitting $0.74 By Investing.com - Investing.com South Africa
PALI stock plunges to 52-week low, hitting $0.74 - Investing.com
Palisade Bio Inc expected to post a loss of $1.99 a shareEarnings Preview - TradingView
Palisade Bio (PALI) Expected to Announce Earnings on Tuesday - Defense World
Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial - Yahoo
Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial -March 14, 2025 at 08:58 am EDT - Marketscreener.com
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire
Palisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative Colitis - Nasdaq
Palisade Bio's UC Treatment Advances: Zero Serious Events as Patient Trial Launches - StockTitan
Palisade Bio to present ulcerative colitis treatment data By Investing.com - Investing.com Australia
Palisade Bio Announces Two Abstracts Selected to be - GlobeNewswire
Palisade Bio to present ulcerative colitis treatment data - Investing.com
Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 - GlobeNewswire
Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Palisade Bio Participates in Virtual Investor 'What This Means” Segment - The Manila Times
Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Can Palisade Bio's Promising UC Drug Candidate Transform Treatment Options? - StockTitan
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Palisade Bio secures Canadian tax credit for drug study By Investing.com - Investing.com Nigeria
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - The Manila Times
Palisade Bio secures Canadian tax credit for drug study - Investing.com India
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Canadian Government Backs This Promising Ulcerative Colitis TreatmentWhat's Behind the $1.39M Investment? - StockTitan
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Autonomix Medical, Inc. Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand - Big News Network
Inside Palisade Bio's Ambitious 2025 Roadmap: 5 Critical Growth Drivers Revealed - StockTitan
PALI stock plunges to 52-week low, touches $1.34 - MSN
Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - BioSpace
PALI-2108 colon-activated prodrug prevents ulcerative colitis progression - BioWorld Online
PALI’s Q2 earnings predictions: What the experts say - US Post News
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire
Q4 Earnings Roundup: Children's Place (NASDAQ:PLCE) And The Rest Of The Apparel Retailer Segment - The Globe and Mail
Palisade Bio's UC Drug Outperforms Standard Treatments in Preclinical StudiesKey Data Unveiled - StockTitan
Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
JPMorgan Chase & Co. Purchases Shares of 8,200 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World
0.78%
2.03%
자본화:
|
볼륨(24시간):